Form 4: Becton Dickinson Executive Sells Shares Under Pre-Arranged Trading Plan

Becton Dickinson's EVP and Chief ISC Officer, David Shan, sold 1,166 shares of common stock for $171.19 per share, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• David Shan, Executive Vice President and Chief ISC Officer of Becton Dickinson & Co (BDX), reported a sale of common stock.
• The transaction involved the disposition of 1,166 shares of BDX common stock.
• The shares were sold at a price of $171.19 per share.
• Following this transaction, David Shan beneficially owns 4,575 shares of Becton Dickinson common stock.
• The sale was executed on June 2, 2025, and was conducted pursuant to a Rule 10b5-1 plan adopted by Mr. Shan on September 5, 2024.

Sentiment

Score: 5

Explanation: The transaction is an insider sale, which can sometimes be perceived negatively. However, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan adopted well in advance (September 5, 2024, for a June 2, 2025 transaction) mitigates concerns about opportunistic selling based on new information, making the sentiment neutral.

Negatives

• An insider sale, even under a 10b5-1 plan, represents a reduction in the executive's direct ownership stake in the company.

Future Outlook

This Form 4 filing reports a past transaction and does not provide any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Becton Dickinson & Co (BDX) operates in the medical technology industry. Insider transactions, such as the sale reported here, are a routine part of executive compensation and personal financial planning across all industries, often managed through pre-arranged 10b5-1 plans to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, which is generally not considered a significant event given the pre-arranged nature of the transaction and the relatively small number of shares compared to the company's total outstanding shares.

Key Dates

Keywords

Becton Dickinson, BDX, Form 4, Insider Trading, Stock Sale, David Shan, 10b5-1 Plan, Medical Technology, Healthcare